Remarkable tethering effect on DNA cleavage of propargylic sulfone conjugates with intercalating moieties

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 2, 1998, Pages 169-174

  Dai, Wei Min ^a   Li, Quan ^a   Fong, Kin Chiu ^a   Chow, Chun Wo ^a   Zhou, Ling ^b   Hamaguchi, Wataru ^b   Nishimoto, Sei Ichi ^b  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; PROPARGYLIC SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; DNA ALKYLATION; DNA CLEAVAGE; DRUG ACTIVITY; DRUG SYNTHESIS; INTERCALATION COMPLEX;

ALKYNES; BACTERIOPHAGE PHI X 174; DNA, VIRAL; ELECTROPHORESIS, AGAR GEL; HYDROLYSIS; INTERCALATING AGENTS; ISATIN;

EID: 0032548455     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10203-7     Document Type: Article

References (37)

1. 1. (a.) Molecular Aspects of Anticancer Drug-DNA Interactions; Neidle, S.; Waring, M. J. Eds.; CRC Press Inc.: Boca Raton, 1993; Vol. 1.
2. (b) Molecular Basis of Specificity in Nucleic Acid-Drug Interactions, Pullman, B; Jortner, J. Eds.; Kluwer Academic Publishers: Dordrecht, 1990.
3. (c) DNA and RNA Cleavers and Chemotherapy of Cancer and Viral Diseases, Meunier, B. Ed.; Kluwer Academic Publishers: Dordrecht, 1996.
4. 2. Cancer Chemotherapeutic Agents; Foye, W. O. Ed.; ACS: Washington, DC, 1995.
5. 3. (a) Nicolaou, K. C.; Skokotas, G.; Maligres, P.; Zuccarello, G.; Schweiger, E. J.; Toshima, K.; Wendeborn, S. Angew. Chem. Int. Ed. Engl. 1989, 28, 1272.
6. (b) Nicolaou, K. C.; Wendeborn, S.; Maligres, P.; Isshiki, K.; Zein, N.; Ellestad, G. Angew. Chem. Int. Ed. Engl. 1991, 30, 418.
7. 4. (a) Sakai, Y.; Bando, Y.; Shishido, K.; Shibuya, M. Tetrahedron Lett. 1992, 33, 957.
8. (b) Toshima, K.; Ohta, K.; Ohtsuka, A.; Matsumura, S.; Nakata, M. J. Chem. Soc., Chem. Commun. 1993, 1406.
9. (c) Kerwin, S. M. Tetrahedron Lett. 1994, 35, 1023.
10. (d) Basak, A.; Khamrai, U. K. Tetrahedron Lett. 1995, 36, 7913.
11. (e) Wu, M.-J.; Lin, C.-F.; Wu, J.-S.; Chen, H.-T. Tetrahedron Lett. 1994, 35, 1879.
12. (f) Wu, M.-J.; Lin, C.-F.; Ong, C.-W. BioMed. Chem. Lett. 1996, 6, 675.
13. (g) Wu, M.-J.; Lin, C.-F.; Chen, H.-T.; Duh, T.-H.; Wang, S.-S.; Hsu, S.-C. BioMed. Chem. Lett. 1996, 6, 2183.
14. (h) Lin, C.-F.; Wu, M.-J. J. Org. Chem. 1997, 62, 4546.
15. (i) Grissom, J. W.; Klingberg, D. Tetrahedron Lett. 1995, 36, 6607.
16. (j) Cao, D.; Kolshorn, H.; Meier, H. Tetrahedron Lett. 1995, 36, 7069.
17. 5. (a) Dai, W.-M.; Fong, K. C. Tetrahedron Lett. 1995, 36, 5613.
18. (b) Dai, W.-M.; Fong, K. C.; Danjo, H.; Nishimoto, S.; Solow, M.; Mak, W. L.; Yeung, M. L. BioMed. Chem. Lett. 1996, 6, 1093.
19. (c) Dai, W.-M.; Fong, K. C.; Danjo, H.; Nishimoto, S. Angew. Chem. Int. Ed. Engl. 1996, 35, 779.
20. 6. (a) Xie, G.; Morgan, A. R.; Lown, J. W. BioMed. Chem. Lett. 1993, 3, 1565.
21. (b) Gupta, R.; Xie, G.; Lown, J. W. Gene 1994, 149, 81.
22. 7. (a) Pindur, U.; Haber, M.; Sattler, K. J. Chem. Edu. 1993, 70, 263.
23. (b) Bailly, C.; Henichart, J.-P. Bioconjugate Chem. 1991, 2, 379.
24. (c) Denny, W. A. In Cancer Chemotherapeutic Agents; Foye, W. O. Ed.; ACS: Washington, DC, 1995; pp. 218-239.
25. 8. Lown, J. W. Chem. Soc. Rev. 1993, 165.
26. 9. Sengupta, S. K. In Cancer Chemotherapeutic Agents; Foye, W. O. Ed.; ACS: Washington, DC, 1995; pp. 205-218.
27. 10. (a) Konishi, M.; Ohkuma, H.; Matsumoto, K.; Tsuno, T.; Kamei, H.; Miyaki, T.; Oki, T.; Kawaguchi, H.; VanDuyne, G. D.; Clardy, J. J. Antibiot. 1989, 42, 1449.
28. (b) Konishi, M.; Ohkuma, H.; Tsuno, T.; Oki, T.; VanDuyne, G. D.; Clardy, J. J. Am. Chem. Soc. 1990, 112, 3715.
29. 11. (a) Sugiura, Y.; Kusakabe, T. In DNA and RNA Cleavers and Chemotherapy of Cancer and Viral Diseases, Meunier, B. Ed.; Kluwer Academic Publishers: Dordrecht, 1996; pp. 65-73.
30. (b) Langley, D. R.; Doyle, T. W.; Beveridge, D. L. J. Am. Chem. Soc. 1991, 113, 4395.
31. (c) Wender, P. A.; Kelly, R. C.; Beckham, S.; Miller, B. L. Proc. Natl. Acd. Sci. USA 1991, 88, 8835.
32. (d) Nicolaou, K. C.; Dai, W.-M. Angew. Chem. Int. Ed. Engl. 1991, 30, 1387.
33. 13C NMR spectra and MS data.
34. 13. Lown, J. W. In Molecular Aspects of Anticancer Drug Action; Neidle, S.; Waring, M. J. Eds.; Verlag Chemie: Weinheim, 1983; pp. 283-314.
35. 14. Due to minor precipitation, the final concentration for 3b,c or 4c may be slightly lower than 1.0 mM.
36. 15. The allenes formed from the propargylic sulfones are chiral and the two enantiomers should interact with DNA differently. For our discussion here, the same enantiomers are compared. Currently, we are working on the molecular modeling in order to obtain 3D structures of the allenes in the bound DNA.
37. 16. The DNA was treated with 0.1 mM ethidium bromide for 2 h before incubating with the sulfones.